Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-343-6 | CAS number: 1562-00-1
Endpoint summary
Administrative data
Description of key information
Acute toxicity after single oral application was tested in male and female rats, which received 5000 mg/kg bw. One female and no male died. The necropsy of the deceased female did not reveal any effect and the death was not found to be treatment-related. The LD50 value for acute oral toxicity is >5000 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
Additional information
Since in the acute oral toxicity study no effects were observed, the LD50 for a single acute oral administration of Sodium 2 -hydroxyethanesulphonate is 5000 mg/kg bw.
Justification for classification or non-classification
Due to the findings described above (LD50 oral in rats >5000 mg/kg bw) Sodium 2 -hydroxyethanesulphonate should not be classified as acute orally toxic.
It can reasonably be deduced that Sodium 2-hydroxyethanesulphonate does not exert systemic toxic effects after dermal application and thus does not have to be classified, because Sodium 2-hydroxyethanesulphonate did not cause lethal effects after administration of a single oral dose of up to 5,000 mg/kg bw in rats. Furthermore the substance does not have to be classified as skin irritating and it is unlikely that higher amounts than tested in the acute oral toxcity study will be systemically available via the intact skin barrier. Therefore, testing is not scientifically necessary.
In accordance with Section 1.2 of REACH Annex XI, there is sufficient weight of evidence from several independent sources of information leading to the conclusion that Sodium 2-hydroxyethansulphonate does not exert systemic toxic effects after acute inhalation exposure and thus does not have to be classified, because
- the LD50value for acute oral toxicity of Sodium 2-hydroxyethansulphonate is >5000 mg/kg bw,
- Sodium 2-hydroxyethansulphonate does not have to be classified as skin/eye irritating, and
- inhalation is very unlikely to occur, since the substance is handled as aqueous solution during production process.
Therefore, it is concluded that testing of acute inhalation toxicity of Sodium 2-hydroxyethansulphonate is not scientifically necessary.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
